These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30256422)

  • 1. Pharmacokinetics of Enoxaparin After Renal Transplantation in Pediatric Patients.
    Damamme A; Urien S; Borgel D; Lasne D; Krug P; Krid S; Charbit M; Salomon R; Treluyer JM; Boyer O
    J Clin Pharmacol; 2018 Dec; 58(12):1597-1603. PubMed ID: 30256422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
    Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
    Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
    Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.
    Hulot JS; Vantelon C; Urien S; Bouzamondo A; Mahé I; Ankri A; Montalescot G; Lechat P
    Ther Drug Monit; 2004 Jun; 26(3):305-10. PubMed ID: 15167633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
    Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR
    Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study.
    Trame MN; Mitchell L; Krümpel A; Male C; Hempel G; Nowak-Göttl U
    J Thromb Haemost; 2010 Sep; 8(9):1950-8. PubMed ID: 20586920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.
    Berges A; Laporte S; Epinat M; Zufferey P; Alamartine E; Tranchand B; Decousus H; Mismetti P;
    Br J Clin Pharmacol; 2007 Oct; 64(4):428-38. PubMed ID: 17509040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.
    Green B; Greenwood M; Saltissi D; Westhuyzen J; Kluver L; Rowell J; Atherton J
    Br J Clin Pharmacol; 2005 Mar; 59(3):281-90. PubMed ID: 15752373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
    Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
    J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin and antifactor Xa levels in pediatric acute burn patients.
    Brown A; Faraklas I; Ghanem M; Cochran A
    J Burn Care Res; 2013; 34(6):628-32. PubMed ID: 24043233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
    J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis.
    Guillet B; Simon N; Sampol JJ; Lorec-Penet AM; Portugal H; Berland Y; Dussol B; Brunet P
    Nephrol Dial Transplant; 2003 Nov; 18(11):2348-53. PubMed ID: 14551364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin Population Pharmacokinetics in the First Year of Life.
    Moffett BS; Galati M; Mahoney D; Lee-Kim Y; Teruya J; Shah MD; Yee DL
    Ther Drug Monit; 2017 Dec; 39(6):632-639. PubMed ID: 28937536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.
    Malinoski D; Jafari F; Ewing T; Ardary C; Conniff H; Baje M; Kong A; Lekawa ME; Dolich MO; Cinat ME; Barrios C; Hoyt DB
    J Trauma; 2010 Apr; 68(4):874-80. PubMed ID: 20386282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
    Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
    Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin in thrombotic disease in children and adolescents.
    Punzalan RC; Hillery CA; Montgomery RR; Scott CA; Gill JC
    J Pediatr Hematol Oncol; 2000; 22(2):137-42. PubMed ID: 10779027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
    Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
    Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
    Ramos-Esquivel A; Salazar-Sánchez L
    Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.